Pencil Beam Scanning in Patients With Renal Tumors

Launched by CHILDREN'S HOSPITAL OF PHILADELPHIA · Jan 17, 2019

Keywords

ClinConnect Summary

This clinical trial, titled "Pencil Beam Scanning in Patients With Renal Tumors," is looking at a new way to treat kidney tumors, specifically Wilms tumor and clear cell sarcoma of the kidney, using a special type of radiation therapy called proton therapy. The main goal of the study is to see if this treatment causes any immediate side effects, known as acute toxicity, in patients who need radiation for their condition. The trial is currently recruiting participants who are 30 years old or younger, have been diagnosed with the specified kidney tumors, and are eligible for radiation treatment.

If you or someone you know is interested in participating, the trial is open to all genders. However, certain conditions must be met: participants should not have received prior radiation therapy in the same area or have undergone chemotherapy for their kidney tumors. Additionally, pregnant or breastfeeding individuals cannot participate. Those who join the study can expect to receive proton therapy and be closely monitored for any potential side effects during the treatment. This research may help improve future treatment options for children and young adults with these types of kidney tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Less than 30 years of age
• • Diagnosis
• • a. Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care including
• • 1. Any patient with favorable histology (FH), stage III disease
• • 2. Any patient with focal or diffuse anaplasia
• • 3. Any patient with CCSK
• • The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK
• Exclusion Criteria:
• • Prior radiotherapy to the region of the study cancer
• • Chemotherapy administered for diagnosis of Wilms tumor or CCSK
• • Pregnant or breastfeeding